Income Statement
LENZ THERAPEUTICS, INC.
LENZ
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
19.09 | - | - | - | - |
|
Cost of Revenue
|
0.42 | - | - | - | - |
|
Gross Profit
|
18.67 | - | - | - | - |
|
Operating Expenses
|
-186.40 | 58.61 | 135.19 | 105.64 | 60.44 |
|
Research & Development
|
18.67 | 29.80 | 32.14 | 72.79 | 37.93 |
|
Selling, General & Administrative
|
91.14 | 28.81 | 40.97 | 32.85 | 22.51 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-91.14 | -58.61 | -135.19 | -105.64 | -60.44 |
|
Non-Operating Income
|
9.51 | 8.84 | 10.54 | 4.59 | -10.32 |
|
Interest Income
|
9.76 | 8.55 | - | - | - |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
-0.24 | 0.29 | 10.95 | 4.59 | 0.02 |
|
Income Before Tax
|
-81.63 | -49.77 | - | - | - |
|
Income Tax Expense
|
0.50 | 0.00 | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-82.13 | -49.77 | -124.65 | -101.05 | -70.80 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-90.85 | -58.55 | -132.78 | -103.29 | -59.71 |
|
Earnings Per Share (Basic)
|
-2.85 | -2.34 | -2.19 | -1.84 | - |
|
Diluted EPS
|
-2.85 | -2.34 | -2.19 | -1.84 | - |
|
Weighted Average Shares
|
28.81 | 21.28 | 57.02 | 54.87 | - |
|
Diluted Weighted Avg Shares
|
28.81 | 21.28 | 57.02 | 54.87 | - |
|
Comprehensive Income
|
-82.08 | -49.58 | - | - | - |